Extended Table 1. Characteristics of 5-ASA users vs non-users in the IBDMDB.
IBD users of 5-ASA were more likely to have ulcerative colitis. Overall, rates of hospitalization and history of bowel surgery were also lower for 5-ASA users compared to non-users.
| Non-users (n=34) | Users (n=45) | p-value | |
|---|---|---|---|
| Age at consent, mean (SD) | 27.7 (17.4) | 26.7 (17.1) | 0.81 |
| Age at diagnosis, mean (SD) | 22.1 (14.2) | 20.9 (11.0) | 0.68 |
| Male (%) | 17 (50) | 21 (47) | 0.95 |
| UC (%) | 6 (18) | 24 (53) | 0.003 |
| Race/ethnicity (%) | |||
| White | 30 (88) | 40 (89) | 0.13 |
| Other | 4 (12) | 5 (11) | |
| Prior bowel surgery (%) | 0.11 | ||
| Yes | 7 (21) | 4 (9) | |
| Antibiotic use (%) | 14 (41) | 25 (56) | 0.30 |
| Bonded 5-ASA use (%)a | 0 (0) | 4 (9) | 0.20 |
| Hospitalized during the study (%) | 13 (38) | 7 (15) | 0.04 |
| Dysbiosisb | 21 (62) | 19 (42) | 0.14 |
a
Bonded 5-ASA formulations include sulfasalazine, balsalazide, and olsalazine
b
As previously defined in the HMP2, Methods22